


Learn2Lose operates as a telehealth weight management clinic serving patients throughout North Carolina, with Dr. David Croland leading clinical oversight of GLP-1 receptor agonist protocols. The practice focuses exclusively on medically supervised weight reduction programs utilizing semaglutide, a peptide medication that mimics the glucagon-like peptide-1 hormone to regulate appetite and glucose metabolism. Patients access the clinic's services entirely through remote consultations, eliminating the need for in-person visits while maintaining physician oversight throughout treatment. The Charlotte-based practice has established a streamlined intake process that includes metabolic assessment, medication titration planning, and ongoing monitoring through virtual check-ins.
Semaglutide therapy at Learn2Lose follows evidence-based dosing protocols that typically begin at 0.25 mg weekly subcutaneous injections, with gradual increases based on individual tolerance and weight loss response. Dr. Croland's approach emphasizes proper injection technique education, side effect management strategies, and realistic expectation setting regarding the timeline for results. The clinic provides patients with detailed guidance on managing common gastrointestinal effects during dose escalation phases, including nausea mitigation through dietary modifications and meal timing adjustments. Patients receive their medication through partnered pharmacies, with the clinic coordinating prescription fulfillment and refill schedules to maintain treatment continuity.
Dr. David Croland brings clinical experience in obesity medicine to the practice, focusing on the physiological mechanisms behind weight regain and metabolic adaptation. His consultation model includes baseline health screening to identify contraindications such as personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. The practice requires patients to maintain regular communication through the telehealth platform, with check-in frequency adjusted based on individual response patterns and any emerging concerns. This monitoring structure allows for timely dose adjustments and intervention if patients experience inadequate weight loss or problematic side effects.
The patient experience at Learn2Lose centers on accessibility for North Carolina residents who face barriers to traditional weight management programs, whether due to geographic distance from specialty clinics, scheduling constraints, or preference for remote care. Initial consultations involve comprehensive review of weight history, previous diet attempts, current medications, and relevant comorbidities such as type 2 diabetes or hypertension. The clinic provides written treatment plans that outline expected timelines, target dose levels, and criteria for assessing treatment success. Patients receive education on the importance of protein intake preservation, hydration maintenance, and physical activity integration to optimize body composition changes during weight loss.
Learn2Lose's telehealth model serves the Charlotte metropolitan area and extends throughout North Carolina, offering appointment availability that accommodates working professionals and individuals with caregiving responsibilities. The practice has accumulated 135 Google reviews with a 5.0-star rating, reflecting patient feedback on appointment accessibility, provider responsiveness, and clarity of treatment instructions. The clinic's focus remains narrow and specialized—semaglutide therapy for weight management—rather than attempting to address multiple aesthetic or wellness concerns. This specialization allows for refined protocols and accumulated clinical experience with GLP-1 agonist therapy specifically, including management of plateau phases and strategies for transitioning to maintenance dosing after goal achievement.
Dr. David Croland
MyPeptideMatch.com is an independent directory. We do not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.


